Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer(INTLECTUAL) | recruiting | Phase 2 | 17 | Seoul National University Bundang HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439497 | Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer(DEHIM_CCRT) | recruiting | Phase 2 | 34 | Samsung Medical CenterOTHER | 1 | Feb 27, 2026 |
| clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06267729 | Study of AZD0754 in Participants With Metastatic Prostate Cancer(APOLLO) | recruiting | Phase 1 / Phase 2 | 60 | AstraZenecaINDUSTRY | 3 | Feb 23, 2026 | clinicaltrials |
| NCT06378346 | GU-01: Glycyrrhizin in Prostate Cancer(GU-01) | recruiting | Phase 2 | 60 | University of Illinois at ChicagoOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | recruiting | Phase 2 | 58 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06111313 | The University of Miami Adapt (UAdapt) Trial | recruiting | Phase 2 | 130 | University of MiamiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06990542 | Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer(RadTARGET) | recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT06591819 | Hypofractionated WPPT With HDR Boost | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07325721 | Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 46 | Medical University of South CarolinaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06397703 | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | recruiting | Phase 2 | 392 | NYU Langone HealthOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06815497 | Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 33 | Tyler J CurielOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07210086 | Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) | recruiting | Phase 2 | 50 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer(PSMA SBRT-SIB) | recruiting | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07054567 | A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer | recruiting | Phase 2 | 96 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05038332 | Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) | recruiting | Phase 2 | 136 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 216 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06536517 | The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | recruiting | Phase 2 | 100 | Johns Hopkins UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06562166 | Online Adaptive Radiotherapy for Cervical Cancer | recruiting | Phase 2 | 124 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06391034 | Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | recruiting | Phase 2 | 161 | Robert Bok, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | recruiting | Phase 2 | 25 | Panagiotis Konstantinopoulos, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06970119 | A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 55 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07080216 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 120 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06084338 | Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | recruiting | Phase 2 | 60 | VA Office of Research and DevelopmentFED | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06463028 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | recruiting | Phase 2 | 40 | Faeth TherapeuticsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299292 | Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | recruiting | Phase 2 | 60 | SMED Clinical ResearchOTHER | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06971744 | Autophagy Maintenance (AUTOMAIN) | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07261683 | Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2026source: clinicaltrials